RIL
NMRA icon

Rothschild Investment LLC’s Neumora Therapeutics NMRA Stock Holding History

Rothschild Investment LLC’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-405
Closed -$405 – 3134
2025
Q1 		$405 Buy
405
+300
+286% +$514 ﹤0.01% 2684
2024
Q4 		$1.11K Hold
105
– – ﹤0.01% 2155
2024
Q3 		$1.39K Buy
105
+90
+600% +$1.05K ﹤0.01% 1936
2024
Q2 		$147 Buy
+15
New +$155 ﹤0.01% 2580

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Rothschild Investment LLC's NMRA Position: Q2 2025 in Review

Rothschild Investment LLC sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 405 shares — an estimated $405 sold.

Rothschild Investment LLC first reported a position in NMRA in Q2 2024 and held it in 4 quarters. The position peaked at $1.39K in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Rothschild Investment LLC reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Rothschild Investment LLC sold 405 Neumora Therapeutics shares in Q2 2025, an estimated $405.
  • Rothschild Investment LLC first reported a position in Neumora Therapeutics in Q2 2024 and held it in 4 quarters.
  • Rothschild Investment LLC's Neumora Therapeutics position peaked at $1.39K in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Rothschild Investment LLC's 13F filing for Q2 2025, filed 11 Aug 2025.